Preeclampsia and the future risk of hypertension: The pregnant evidence

Current Hypertension Reports

Volumn 15, Issue 2, 2013, Pages 114-121

  Garovic, Vesna D ^a   August, Phyllis ^b  

^a MAYO CLINIC   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cardiovascular disease; Hypercoagulability; Hypertension; Inflammatory response; Metabolic abnormalities; Preeclampsia; Pregnancy; Risk factors

Indexed keywords

ADULT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE REPORT; CORONARY ARTERY DISEASE; FEMALE; GESTATIONAL AGE; HEALTH CARE DELIVERY; HUMAN; HYPERTENSION; INFLAMMATION; MATERNAL HYPERTENSION; MATERNAL MORTALITY; MEDICAL CARE; PREECLAMPSIA; PREGNANCY; PREGNANCY TOXEMIA; PREVALENCE; PROTEINURIA; REVIEW; RISK FACTOR; UNITED STATES;

FEMALE; FORECASTING; HUMANS; HYPERTENSION; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 84879605680     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0329-4     Document Type: Review

References (70)

1. Anonymous: Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.[comment]. Am J Obstet and Gynecol 2000, 183(1):S1-S22.
2. • Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009;113(6):1299-306. This paper examines trends in the rates of hypertensive disorders in pregnancy in the USA in 1998-2000, and reports that the number of delivery hospitalizations with hypertensive disorders in pregnancy is increasing, and that these hospitalizations are associated with a substantial burden of severe obstetric morbidity.
3. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994;101(8):669-74.
4. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93(10):1049-59.
5. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science. 1997;277(5332):1669-72.
6. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis.[see comment]. BMJ. 2007;335(7627):974.
7. •• Ray JG, Schull MJ, Kingdom JC, Vermeulen MJ. Heart failure and dysrhythmias after maternal placental syndromes: HAD MPS Study. Heart. 2012;98(15):1136-41. This paper was the first to report the association between maternal placental syndromes, including preeclampsia, and a higher risk of premature HF and dysrhythmias, especially when perinatal morbidity is present.
8. Corwin J, Herrick WW. Relation of hypertensive toxemia of pregnancy to chronic cardiovascular disease. JAMA. 1927;88:457-9.
9. Chesley SC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol. 1976;124(5):446-59.
10. Chesley LC. Recognition of the long-term sequelae of eclampsia. Am J Obstet Gynecol. 2000;182(1 Pt 1):249-50.
11. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis. 2008;2(4):249-59.
12. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Hear J. 2008;156(5):918-30.
13. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol. 1986;155(5):1011-6.
14. Selvaggi L, Loverro G, Schena FP, Manno C, Cagnazzo G. Long term follow-up of women with hypertension in pregnancy. Int J Gynaecol Obstet. 1988;27(1):45-9.
15. Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine. 1981;60(4):267-76.
16. Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP, et al. Guidelines for the management of hyertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol. 2009;49:242-6.
17. Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb JD, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens. 2010;28(4):826-33.
18. •• Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation. 2011;123(11):1243-62. These are the first guidelines for for the prevention of cardiovascular disease in women that recognize the association between pregnancy conditions, and preeclampsia in particular, and future cardiovascular disease.
19. Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol. 2007;3(11):613-22.
20. Islami D, Shoukir Y, Dupont P, Campana A, Bischof P. Is cellular fibronectin a biological marker for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol. 2001;97(1):40-5.
21. Friedman SA, Schiff E, Emeis JJ, Dekker GA, Sibai BM. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol. 1995;172(1 Pt 1):202-3.
22. Halim A, Kanayama N, el Maradny E, Nakashima A, Bhuiyan AB, Khatun S, et al. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am J Obstet Gynecol. 1996;174(1 Pt 1):272-7.
23. Krauss T, Kuhn W, Lakoma C, Augustin HG. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am J Obstet Gynecol. 1997;177(2):443-9.
24. Greer IA, Lyall F, Perera T, Boswell F, Macara LM. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol. 1994;84(6):937-40.
25. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia.[see comment]. Br J Obstet Gynaecol. 1995;102(1):20-5.
26. Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide. 2000;4(4):441-58.
27. Parthasarathy S, Santanam N. Mechanisms of oxidation, antioxidants, and atherosclerosis. Curr Opin Lipidol. 1994;5(5):371-5.
28. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.[see comment]. J Clin Investig. 2003;111(5):649-58.
29. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension. 2012;59(3):740-6.
30. Sibai BM, Gordon T, Thom E, Caritis SN, Klebanoff M, McNellis D, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The national institute of child health and human development network of maternal-fetal medicine Units. Am J Obstet Gynecol. 1995;172(2 Pt 1):642-8.
31. Kaaja R. Insulin resistance syndrome in preeclampsia. Semin Reprod Endocrinol. 1998;16(1):41-6.
32. •• Staff AC, Dechend R, Pijnenborg R. Learning from the placenta: acute atherosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health. Hypertension. 2010;56(6):1026-34. This review summarizes normal and pathological vessel remodeling in pregnancy and discuss similarities and differences between preeclampsia and arteriosclerosis.
33. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group.[comment]. Am J Obstet Gynecol. 1997;177(5):1003-10.
34. Dunne F, Brydon P, Smith K, Gee H. Pregnancy in women with Type 2 diabetes: 12 years outcome data 1990-2002. Diabet Med. 2003;20(9):734-8.
35. Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc. 1999;58(1):163-9.
36. Hubel CA, Lyall F, Weissfeld L, Gandley RE, Roberts JM. Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metab Clin Exp. 1998;47(10):1281-8.
37. Sattar N, Bendomir A, Berry C, Shepherd J, Greer IA, Packard CJ. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol. 1997;89(3):403-8.
38. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).[see comment]. Circulation. 2001;104(25):3052-6.
39. Teppa RJ, Ness RB, Crombleholme WR, Roberts JM. Free leptin is increased in normal pregnancy and further increased in preeclampsia. Metab Clin Exp. 2000;49(8):1043-8.
40. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, et al. Platelet activation in obese women: role of inflammation and oxidant stress.[see comment]. JAMA. 2002;288(16):2008-14.
41. Szekeres-Bartho J. Immunological relationship between the mother and the fetus. Int Rev Immunol. 2002;21(6):471-95.
42. Muller I, Munder M, Kropf P, Hansch GM. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol. 2009;30(11):522-30.
43. Thomson AJ, Telfer JF, Young A, Campbell S, Stewart CJ, Cameron IT, et al. Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process. Hum Reprod. 1999;14(1):229-36.
44. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis.[see comment]. Am J Obstet Gynecol. 1998;179(1):80-6.
45. Austgulen R, Lien E, Vince G, Redman CW. Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 1997;71(1):53-8.
46. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia.[see comment]. Hypertension. 2004;44(5):708-14.
47. Cadden KA, Walsh SW. Neutrophils, but not lymphocytes or monocytes, infiltrate maternal systemic vasculature in women with preeclampsia. Hypertens Pregnancy. 2008;27(4):396-405.
48. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol. 2001;98(5 Pt 1):757-62.
49. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801-9.
50. Ostlund E, Hansson LO, Bremme K. Fibronectin is a marker for organ involvement and may reflect the severity of preeclampsia. Hypertens Pregnancy. 2001;20(1):79-87.
51. Powers RW, Evans RW, Ness RB, Crombleholme WR, Roberts JM. Homocysteine and cellular fibronectin are increased in preeclampsia, not transient hypertension of pregnancy. Hypertens Pregnancy. 2001;20(1):69-77.
52. Shaarawy M, Didy HE. Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynaecol Obstet. 1996;55(2):135-9.
53. Paternoster D, Stella A, Simioni P, Trovo S, Plebani P, Girolami A. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet. 1994;47(3):215-21.
54. Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol. 2000;96(1):45-9.
55. Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol. 2005;105(1):182-92. doi: 10.1097/01.AOG. 0000146250.85561.e9.
56. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27(3):517-27.
57. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metab Clin Exp. 1993;42(8):945-9.
58. Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol. 2003;1(1):111.
59. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001;285(12):1607-12.
60. North RA, Simmons D, Barnfather D, Upjohn M. What happens to women with preeclampsia? Microalbuminuria and hypertension following preeclampsia. Aust N Z J Obstet Gynaecol. 1996;36(3):233-8.
61. • Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension. 2011;58(4):709-15. This study evaluated the postpartum natural history and clinical significance of asymptomatic left ventricular impairment known to occur with preeclampsia, and concludes that the cardiovascular implications of preeclampsia do not end with the birth of the infant and placenta.
62. Bamfo JE, Kametas NA, Chambers JB, Nicolaides KH. Maternal cardiac function in normotensive and pre-eclamptic intrauterine growth restriction. Ultrasound Obstet Gynecol. 2008;32(5):682-6.
63. Zandstra M, Stekkinger E, van der Vlugt MJ, van Dijk AP, Lotgering FK, Spaanderman ME. Cardiac diastolic dysfunction and metabolic syndrome in young women after placental syndrome. Obstet Gynecol. 2010;115(1):101-8.
64. Nisell H, Lintu H, Lunell NO, Mollerstrom G, Pettersson E. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol. 1995;102(11):876-81.
65. Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart. 1997;77(2):154-8.
66. Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J. Long-term prognosis of hypertension in pregnancy. Hypertens Pregnancy. 2000;19(2):199-209.
67. Hubel CA, Snaedal S, Ness RB, Weissfeld LA, Geirsson RT, Roberts JM, et al. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG: Intl J Obstet Gynaecol. 2000;107(6):776-84.
68. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326(7394):845. doi: 10.1136/bmj.326.7394.845.
69. Sattar N, Ramsay J, Crawford L, Cheyne H, Greer IA. Classic and novel risk factor parameters in women with a history of preeclampsia. Hypertension. 2003;42(1):39-42.
70. Diehl CL, Brost BC, Hogan MC, Elesber AA, Offord KP, Turner ST, et al. Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. Am J Obstet Gynecol. 2008;198(5):e11-3.